SEC Form 4 · accession 0001562180-18-003854
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer K. Moses
Officer — VP of Finance & Admin
Period of report
Sep 5, 2018
Accepted (ET)
Sep 6, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 5, 2018 | M | 750 | $0.39 | A | 750 | D | |
| Common Stock | Sep 5, 2018 | S | 750 | $59.60 | D | 0 | D | |
| Common Stock | Sep 5, 2018 | M | 2,000 | $3.72 | A | 2,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F2 | $3.72 | Sep 5, 2018 | M | 2,000 | D | — | Dec 21, 2025 | Common Stock | 2,000 | 12,333 | D |
| Stock Options (Right to Buy)F3 | $0.39 | Sep 5, 2018 | M | 750 | D | — | Jul 11, 2024 | Common Stock | 750 | 3,916 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2The shares underlying this option vested as to 25% of the shares on December 16, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- F3All shares underlying this option have vested.